Trabectedin and Durvalumab Combination Is Feasible and Active in Relapsing Ovarian Cancer

Antonia Digklia; George Coukos; Krisztian Homicsko

doi:10.1158/1078-0432.CCR-21-4592

Trabectedin and Durvalumab Combination Is Feasible and Active in Relapsing Ovarian Cancer

Clin Cancer Res. 2022 May 2;28(9):1745-1747. doi: 10.1158/1078-0432.CCR-21-4592.

Authors

Antonia Digklia^{1

2}, George Coukos^{2

3

4}, Krisztian Homicsko^{2

3

4

5}

Affiliations

¹ Department of Oncology, Medical Oncology Service, Lausanne University Hospital, Lausanne, Switzerland.
² University of Lausanne, Lausanne, Switzerland.
³ Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland.
⁴ Department of Oncology, Immuno-oncology Service, Lausanne University Hospital, Lausanne, Switzerland.
⁵ Center for Personalized Oncology, Lausanne University Hospital (CHUV), Lausanne, Switzerland.

PMID: 35176150
DOI: 10.1158/1078-0432.CCR-21-4592

Abstract

The combination of chemotherapy and immune therapies still promises to synergize for prolonged tumor control. However, the quest for optimal combinations tailored for tumor histology remains ongoing. A recent study provides evidence on the feasibility of the trabectedin/durvalumab combination and reports on interesting preliminary efficacy. See related article by Toulmonde et al., p. 1765.

Publication types

Editorial
Comment

MeSH terms

Antibodies, Monoclonal
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Carcinoma, Ovarian Epithelial / drug therapy
Dioxoles / adverse effects
Female
Humans
Neoplasm Recurrence, Local / drug therapy
Ovarian Neoplasms* / drug therapy
Ovarian Neoplasms* / pathology
Sarcoma* / drug therapy
Soft Tissue Neoplasms* / drug therapy
Tetrahydroisoquinolines* / adverse effects
Trabectedin

Substances

Antibodies, Monoclonal
Dioxoles
Tetrahydroisoquinolines
durvalumab
Trabectedin